Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q4 2021 Earnings Conference Call November 22, 2021 4:30 AM ET Company Participants Dr. Jay Luly – President and Chief Executive Officer Jennifer Viera – Investor Relations Paul Mellett – CFO Nathalie Adda – Chief Medical Officer Conference Call Participants Brian Abrahams – RBC Capital Markets Akash Tewari – Jefferies Unidentified Analyst 1 – Piper Sandler Brian Skorney – Baird Roy Buchanan – JMP Securities Eric Joseph – JP Morgan Zegbeh Jallah – Roth Capital Part ...

E N A N T A Pharmaceuticals CREATING SMALL MOLECULE DRUGS FOR VIRAL INFECTIONS AND LIVER DISEASES Corporate Presentation September 13, 2021 Forward Looking Statements Disclaimer This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our research and development programs, our business and the industry in which we operate. Any statements contained herein that are not statements of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 2834 04-3205099 (State or other jurisdiction of incorporation or organizati ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q3 2021 Earnings Conference Call August 5, 2021 4:30 PM ET Company Participants Jennifer Viera - Investor Relations Dr. Jay Luly - President and CEO Paul Mellett - Chief Financial Officer Nathalie Adda - Chief Medical Officer Conference Call Participants Brian Skorney - Baird Swapnil Malekar - Piper Sandler Brian Abrahams - RBC Capital Markets Roy Buchanan - JMP Securities Zegbeh Jallah - ROTH Capital Markets Operator Good afternoon. And welcome to Enanta Pharmaceu ...

业绩总结 - Enanta在2020财年总收入为1.225亿美元，2021财季总收入为2010万美元[68] - 2020财年研发费用为1.368亿美元，2021财季研发费用为4150万美元[68] - 2020财年一般管理费用为2740万美元，2021财季一般管理费用为830万美元[68] - 2020财年净亏损为3620万美元，2021财季净亏损为2200万美元[68] - 2020财年每股稀释净亏损为1.81美元，2021财季每股稀释净亏损为1.09美元[68] - 2020财年现金、现金等价物及可市场证券总额为4.193亿美元，2021财季为4.004亿美元[68] 用户数据 - 全球约有2.9亿人感染慢性HBV，每年有超过20万至30万人因肝硬化和肝细胞癌死亡[41] - RSV在全球每年造成3300万例病例，全球住院人数为300万[20] - 在美国，RSV导致的住院人数为177,000，死亡人数为14,000[20] - NASH在美国的患者人数预计在2030年将达到650万至1630万[57] 新产品和新技术研发 - EDP-938在临床试验中显示出71%和74%的病毒载量减少，P值均小于0.001[25] - EDP-938在临床试验中对RSV症状的减轻效果为68%和74%，P值均小于0.001[26] - EDP-938在第一阶段试验中，主要和关键次要疗效终点均达成，P值小于0.001[23] - EDP-938在第二阶段试验中，C峰浓度约为EC90的20-40倍[23] - Enanta的RSV L-蛋白抑制剂对RSV-A和RSV-B具有纳摩尔级的效力[36] - EDP-514在小鼠模型中经过12周治疗后，HBV病毒滴度减少超过4个对数[44] - EDP-514在NUC抑制患者中，HBV RNA的平均减少为1个对数，而安慰剂组为0.3个对数[48] - EDP-514在HBV阳性患者中，最大HBV RNA减少为4.8个对数，安慰剂组为1.9个对数[51] - EDP-721在AAV-HBV小鼠模型中，HBsAg水平在14天内减少约3个对数[54] - EDP-305在ARGON-1研究中，使用2.5毫克剂量时，主要安全性终点在12周内达成[60] - EDP-305在治疗期间，1毫克剂量的瘙痒发生率为1.8%，而2.5毫克剂量为20.8%[61] - EDP-514获得FDA快速通道认证，显示出对HBV的强效抗病毒活性[44] - EDP-721在体内显示出对HBV RNA的强效去稳定作用，具有潜在的功能治愈能力[52] 市场扩张和并购 - Glecaprevir的2021年销售额为25亿美元，预计将获得50%净销售的双位数特许权使用费[67] 未来展望 - EDP-514在NUC抑制的HBV患者中的1b期临床试验已启动，初步数据预计在2021年第二季度报告[70] - Enanta的EDP-938获得FDA的快速通道认证[22]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) DELAWARE 2834 04-3205099 (State or other jurisdiction of incorporation or organizat ...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2021 Earnings Conference Call May 6, 2021 4:30 PM ET Company Participants Jennifer Viera - Investor Relations Jay Luly - President and Chief Executive Officer Paul Mellett - Chief Financial Officer Nathalie Adda - Chief Medical Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Yasmeen Rahimi - Piper Sandler Eric Joseph - J.P. Morgan Roy Buchanan - JMP Securities LLC Brian Skorney - Robert W. Baird & Co. William Lee - Wolfe Research, LLC Z ...

E N A N T A Pharmaceuticals CREATING SMALL MOLECULE DRUGS FOR VIRAL INFECTIONS AND LIVER DISEASES Corporate Presentation May 6, 2021 Forward Looking Statements Disclaimer This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our research and development programs, our business and the industry in which we operate. Any statements contained herein that are not statements of histori ...

E N A N T A Pharmaceuticals CREATING SMALL MOLECULE DRUGS FOR VIRAL INFECTIONS AND LIVER DISEASES Corporate Presentation March 16, 2021 Forward Looking Statements Disclaimer This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our research and development programs, our business and the industry in which we operate. Any statements contained herein that are not statements of hist ...

E N A N T A Pharmaceuticals CREATING SMALL MOLECULE DRUGS FOR VIRAL INFECTIONS AND LIVER DISEASES Corporate Overview February 25, 2021 Forward Looking Statements Disclaimer This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our research and development programs, our business and the industry in which we operate. Any statements contained herein that are not statements of histo ...